Unleashing the Potential of Immuno-Oncology Therapies November 9, 2022 Placeholder area for citations and references 1 © 2022 Xilio Therapeutics, Inc. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding plans, timing and expectations related to the initiation of patient enrollment in a monotherapy expansion cohort for the Phase 1 clinical tr ...

| --- | --- | --- | --- | --- | --- | --- | |-------|----------------------------------------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | XILIO THERAPEUTICS (NASDAQ: XLO) | | | | | | | | HARNESSING THE IMMUNE SYSTEM TO IMPROVE THE LIVES OF PEOPLE WITH CANCER MARCH 1, 2022 | | | | | | © 2022 Xilio Therapeutics, Inc. Forward-looking st ...